Eli Lilly and Company $LLY Shares Purchased by Cary Street Partners Financial LLC

Cary Street Partners Financial LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 1.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 28,543 shares of the company’s stock after buying an additional 492 shares during the quarter. Eli Lilly and Company makes up approximately 0.8% of Cary Street Partners Financial LLC’s investment portfolio, making the stock its 26th largest position. Cary Street Partners Financial LLC’s holdings in Eli Lilly and Company were worth $30,675,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the stock. Cidel Asset Management Inc. grew its holdings in shares of Eli Lilly and Company by 26.5% during the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock worth $20,392,000 after purchasing an additional 5,591 shares during the period. Spire Wealth Management boosted its holdings in Eli Lilly and Company by 2.2% during the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock valued at $29,789,000 after acquiring an additional 592 shares during the period. Coldstream Capital Management Inc. boosted its stake in shares of Eli Lilly and Company by 25.6% in the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after buying an additional 8,659 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Eli Lilly and Company by 30.8% in the 4th quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after buying an additional 7,338 shares during the period. Finally, Teachers Retirement System of The State of Kentucky increased its holdings in Eli Lilly and Company by 3.5% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock valued at $126,022,000 after buying an additional 5,595 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Bank of America cut their target price on Eli Lilly and Company from $1,294.00 to $1,133.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Guggenheim reiterated a “buy” rating and issued a $1,183.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Scotiabank reiterated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,220.37.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,066.59 on Tuesday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The stock has a market cap of $1.00 trillion, a price-to-earnings ratio of 37.89, a price-to-earnings-growth ratio of 1.16 and a beta of 0.48. The business has a fifty day moving average of $944.65 and a 200-day moving average of $1,005.65. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the previous year, the firm posted $3.34 earnings per share. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts predict that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: UBS said Lilly’s late-stage retatrutide data showed strong obesity efficacy and a clear dose-response, with the highest dose producing about 28% weight loss at 80 weeks, reinforcing Lilly’s position in the fast-growing obesity market. Eli Lilly weight loss drug data supports long-term obesity market position, says UBS
• Positive Sentiment: Phase 1b Heart-2 results for VERVE-102 were reported as highly encouraging, with a single dose reducing PCSK9 by up to 88% and LDL-C by up to 62%, supporting Lilly’s case for a potential one-time treatment in high-risk cholesterol patients. A single dose of Lilly’s PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
• Positive Sentiment: Several market commentators highlighted Lilly as a long-term growth and “must-own” type of stock, which can reinforce investor confidence and keep sentiment constructive. Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Independent stock-picking articles and hedge-fund stake updates included Lilly among attractive holdings, but these were mostly portfolio commentary rather than company-specific fundamentals. 5 Best Stocks for a Couch Potato portfolio
• Negative Sentiment: A separate lawsuit headline about drug reimbursements adds some legal overhang, though it appears less important than the recent positive pipeline news. COGIC responds after Eli Lilly files lawsuit over drug reimbursements

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.